Karina Zeyer

Dr. Karina Zeyer


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
KZKarina Zeyer
Karina Zeyer
OBOlivier Bornert
Olivier Bornert
VNValentin Nelea
Valentin Nelea
XBXinyi Bao
Xinyi Bao
ALAlexandre Leytens
Alexandre Leytens
ANAlexander Nyström
Alexander Nyström
Fibronectin serves as a platform to guide and facilitate deposition of collagen and fibrillin microfibrils. During development of fibrotic diseases, altered fibronectin deposition in the extracellular matrix (ECM) is generally an early event. Following this, dysregulated organization of fibrillins and fibrillar collagens occurs. Because fibronectin is an essential orchestrator of healthy ECM, perturbation of its ECM-organizational capacity may be involved in development of fibrosis. To investigate this, we employed recessive dystrophic epidermolysis bullosa (RDEB) as a disease model with progressive, severe dermal fibrosis. Fibroblasts from RDEB donors in 2D and 3D cultures displayed dysregulated fibronectin deposition. Our analyses revealed that increase of pro-fibrotic DPP4+ fibroblasts coincides with altered fibronectin deposition. DPP4 inhibitors normalized deposition of fibronectin and subsequently of fibrillin microfibrils and collagen I. Intriguingly, proteomics, inhibitor and mutagenesis studies disclosed that DPP4 modulates ECM deposition through proteolysis of the fibronectin N-terminus. Our study provides mechanistic insights to the observed pro-fibrotic activities of DPP4 and extends the understanding of fibronectin-guided ECM assembly in health and disease.

25 October 2025 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
KZKarina Zeyer
Karina Zeyer
STStefan Tholen
Stefan Tholen
OSOliver Schilling
Oliver Schilling
LGLeonie Gerling
Leonie Gerling
MMMarina Morath
Marina Morath
ASAnke Schumann
Anke Schumann
Propionic aciduria (PA‐uria) and methylmalonic aciduria (MMA‐uria) are caused by defects in propionate catabolism. While chronic kidney disease (CKD) is a well‐established complication in MMA‐uria, renal involvement in PA‐uria has only come into focus more recently, and the underlying mechanisms remain poorly understood. We investigated human renal epithelial cells from patients with PA‐uria, MMA‐uria, and healthy controls under metabolic stress, induced by methylmalonic acid, methylcitric acid, high‐protein, or isoleucine/valine‐enriched media. Proteomic profiling revealed significant enrichment of extracellular matrix (ECM)‐related pathways in PA‐uria cells. Both PA‐uria and MMA‐uria cells exhibited increased deposition of fibronectin and collagen fibers, which were further amplified under metabolic stress conditions. Transforming growth factor beta (TGF‐β) signaling was identified as a key pro‐fibrotic pathway. Pharmacological inhibition of the TGF‐β receptor signaling normalized fibronectin and collagen deposition in both PA‐uria and MMA‐uria cells. Treatment with losartan, an angiotensin II type 1 receptor blocker known to modulate TGF‐β signaling, also reversed the enhanced ECM deposition. This is the first study to mechanistically link ECM remodeling and TGF‐β signaling to CKD pathogenesis in both PA‐uria and MMA‐uria. Our findings highlight fibrotic remodeling as a shared pathogenic feature and suggest that losartan, a widely available and well‐tolerated drug, could be repurposed to mitigate renal fibrosis in these disorders.

5 July 2026 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
KZKarina Zeyer
Karina Zeyer
TDTerry G.J. Derks
Terry G.J. Derks
MLMirjam Langeveld
Mirjam Langeveld
EMElaine Murphy
Elaine Murphy
ARAlessandro Rossi
Alessandro Rossi
AZAthanasia Ziagaki
Athanasia Ziagaki
Long-chain fatty acid oxidation disorders (LcFAODs) are rare inherited disorders associated with impaired energy metabolism and increased risk of metabolic decompensation during catabolic stress. With improved diagnosis and care, affected women reach reproductive age, making pregnancy management an emerging clinical challenge. We conducted an international, web-based survey among 55 metabolic centers from 21 countries to assess clinical management of pregnancies in women with lcFAODs focusing on management strategies rather than pregnancy outcomes. The 23-item questionnaire addressed preconception counseling, monitoring strategies, dietary management, peripartum care, postpartum follow-up, and neonatal management. Among respondents, 65% had managed pregnancies in women with lcFAODs, reporting 131 cases, most commonly in CPT2 (n = 52) and VLCAD (n = 44) deficiencies. Preconception counseling and genetic consultation were widely recommended (>85%). Core management principles included dietary adaptation with restriction of long-chain fatty acids, supplementation with medium-chain triglycerides, and prevention of catabolism. Marked inter-center variability was observed in monitoring frequency, biochemical parameters, and follow-up intensity. Creatine kinase was the most used biochemical marker for monitoring metabolic stability. Multidisciplinary care was endorsed but inconsistently implemented, with approximately half of the centers reporting structured multidisciplinary meetings. Individualized peripartum plans were nearly universal, and delivery in specialized centers was generally recommended. Pregnancy in women with lcFAODs is generally considered feasible and safe under specialist metabolic and obstetric care. However, management remains highly heterogeneous, particularly regarding monitoring and multidisciplinary structures. These findings highlight the need for international consensus and standardized care frameworks to optimize maternal and neonatal outcomes.